MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 07-31-2025
Alphatec Holdings Operating Income 2011-2025 | ATEC
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Alphatec Holdings
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -136 M | -173 M | -147 M | -128 M | -58.9 M | -47.3 M | -22.4 M | -9 M | -15.4 M | -176 M | 1.48 M | -73.4 M | -9.84 M | -24.5 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.48 M | -176 M | -72.8 M |
Quarterly Operating Income Alphatec Holdings
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -13.1 M | -44.3 M | - | -33.7 M | -35.3 M | -43.3 M | - | -38.4 M | -49.9 M | -40.3 M | - | -35 M | -35.7 M | -41.2 M | - | -35.1 M | -35.8 M | -19 M | - | -12.9 M | -11.2 M | -17.8 M | - | -11.6 M | -10.4 M | -10.8 M | - | -7.53 M | -6.54 M | -667 K | - | -1.26 M | -735 K | -3.4 M | - | -4.55 M | -320 K | -3.44 M | - | -165 M | -2.83 M | 1.14 M | - | 1.73 M | 1.84 M | -4.7 M | - | -13.2 M | -2.9 M | -1.36 M | - | -1.97 M | -3.75 M | -126 K | - | -2.36 M | -3.3 M | -2.36 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.84 M | -165 M | -18.2 M |
Operating Income of other stocks in the Medical devices industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Abiomed
ABMD
|
230 M | - | - | $ 17.2 B |  USA |
 |
Acutus Medical
AFIB
|
-11.7 M | - | -26.83 % | $ 2.62 M | USA |
 |
Apyx Medical Corporation
APYX
|
-17.3 M | $ 3.82 | -1.04 % | $ 132 M | USA |
 |
Bio-Rad Laboratories
BIO
|
269 M | $ 307.08 | -0.33 % | $ 8.66 B | USA |
 |
Apollo Endosurgery
APEN
|
-31.4 M | - | - | $ 475 M | USA |
 |
BioSig Technologies
BSGM
|
-12.9 M | - | 37.08 % | $ 85.7 M | USA |
 |
Bruker Corporation
BRKR
|
253 M | $ 45.69 | 1.24 % | $ 6.81 K | USA |
 |
Allied Healthcare Products
AHPI
|
-1.27 M | - | 3.58 % | $ 2.21 M | USA |
 |
Abbott Laboratories
ABT
|
6.82 B | $ 128.67 | 2.55 % | $ 224 B | USA |
 |
Boston Scientific Corporation
BSX
|
2.6 B | $ 91.95 | -0.67 % | $ 135 B | USA |
 |
Conformis
CFMS
|
-46.3 M | - | - | $ 16.4 M | USA |
 |
EDAP TMS S.A.
EDAP
|
-20.5 M | $ 3.18 | 10.56 % | $ 119 M |  France |
 |
Cardiovascular Systems
CSII
|
-35.8 M | - | 0.15 % | $ 844 M | USA |
 |
Cutera
CUTR
|
-156 M | - | -10.19 % | $ 1.99 M | USA |
 |
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M |  Canada |
 |
Eargo
EAR
|
-112 M | - | - | $ 10.2 M | USA |
 |
Dynatronics Corporation
DYNT
|
-2.45 M | - | 14.99 % | $ 929 K | USA |
 |
Cognyte Software Ltd.
CGNT
|
-5.13 M | $ 9.58 | -2.84 % | $ 688 M |  Israel |
 |
InMode Ltd.
INMD
|
113 M | $ 14.35 | -1.1 % | $ 1.14 B | Israel |
 |
IRIDEX Corporation
IRIX
|
-10 M | $ 0.99 | 7.52 % | $ 16 M | USA |
 |
IRadimed Corporation
IRMD
|
22 M | $ 96.99 | 0.79 % | $ 1.23 B | USA |
 |
Second Sight Medical Products
EYES
|
-24.7 M | - | -0.97 % | $ 54.4 M | USA |
 |
Align Technology
ALGN
|
608 M | $ 163.04 | -1.44 % | $ 12.2 B | USA |
 |
Accuray Incorporated
ARAY
|
7.84 M | $ 1.04 | -2.06 % | $ 107 M | USA |
 |
Avinger
AVGR
|
-16.6 M | - | -20.74 % | $ 369 K | USA |
 |
ClearPoint Neuro
CLPT
|
-19.7 M | $ 12.5 | -1.66 % | $ 338 M | USA |
 |
FONAR Corporation
FONR
|
5.31 M | $ 14.9 | 0.99 % | $ 97.7 M | USA |
 |
AxoGen
AXGN
|
-3.29 M | $ 30.0 | -1.3 % | $ 1.33 B | USA |
 |
Axonics Modulation Technologies
AXNX
|
-64.9 M | - | - | $ 3.31 B | USA |
 |
GBS
GBS
|
-10.6 M | - | -0.57 % | $ 7.12 M | USA |
 |
CONMED Corporation
CNMD
|
200 M | $ 40.3 | -1.29 % | $ 1.24 B | USA |
 |
LivaNova PLC
LIVN
|
129 M | $ 63.28 | 0.84 % | $ 3.43 B |  Britain |
 |
OrthoPediatrics Corp.
KIDS
|
-35 M | $ 17.83 | 1.31 % | $ 411 M | USA |
 |
Globus Medical
GMED
|
166 M | $ 86.73 | 0.05 % | $ 11.8 B | USA |
|
LENSAR
LNSR
|
-10.7 M | $ 11.51 | -0.04 % | $ 133 M | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
28.4 M | $ 13.51 | 0.67 % | $ 1.04 B | USA |
 |
Aziyo Biologics
AZYO
|
-30.5 M | - | 1.37 % | $ 20.5 M | USA |
 |
Aethlon Medical
AEMD
|
-9.34 M | $ 3.07 | -9.71 % | $ 4.79 M | USA |
 |
Establishment Labs Holdings
ESTA
|
-50 M | $ 72.39 | -0.17 % | $ 2.04 B |  Costa-rica |